Pfizer Receives FDA Approval for Elranatamab in Relapsed/Refractory Multiple Myeloma
Pfizer announces FDA approval of elranatamab (Elrexfio) for adults with relapsed or refractory multiple myeloma after at least four prior lines of therapy.
Pfizer Inc. today announced that the FDA has granted accelerated approval to Elrexfio (elranatamab-bcmm), a bispecific antibody targeting BCMA and CD3, for the treatment of adults with relapsed or refractory multiple myeloma who have received at least four prior lines of therapy. In the MagnetisMM-3 trial, elranatamab demonstrated an overall response rate of 61% with a median duration of response of 17.1 months. The safety profile was manageable, with cytokine release syndrome and neurotoxicity being the most common adverse events. This approval provides a new treatment option for heavily pre-treated myeloma patients.
Original Source
Business Wire